- Home
- IFRX vs WYY Comparison
IFRX vs WYY Comparison
Compare IFRX & WYY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IFRX
- WYY
- Stock Information
- Founded
- IFRX 2007
- WYY 1991
- Country
- IFRX Germany
- WYY United States
- Employees
- IFRX N/A
- WYY N/A
- Industry
- IFRX Biotechnology: Pharmaceutical Preparations
- WYY EDP Services
- Sector
- IFRX Health Care
- WYY Technology
- Exchange
- IFRX Nasdaq
- WYY Nasdaq
- Market Cap
- IFRX 53.5M
- WYY 55.2M
- IPO Year
- IFRX 2017
- WYY 1998
- Fundamental
- Price
- IFRX $1.14
- WYY $5.38
- Analyst Decision
- IFRX Strong Buy
- WYY Strong Buy
- Analyst Count
- IFRX 5
- WYY 2
- Target Price
- IFRX $7.40
- WYY $7.50
- AVG Volume (30 Days)
- IFRX 1.0M
- WYY 86.3K
- Earning Date
- IFRX 11-07-2025
- WYY 11-12-2025
- Dividend Yield
- IFRX N/A
- WYY N/A
- EPS Growth
- IFRX N/A
- WYY N/A
- EPS
- IFRX N/A
- WYY N/A
- Revenue
- IFRX $191,224.00
- WYY $144,421,640.00
- Revenue This Year
- IFRX N/A
- WYY $9.19
- Revenue Next Year
- IFRX $1,216.24
- WYY $13.16
- P/E Ratio
- IFRX N/A
- WYY N/A
- Revenue Growth
- IFRX 54.36
- WYY 16.25
- 52 Week Low
- IFRX $0.71
- WYY $2.19
- 52 Week High
- IFRX $2.82
- WYY $6.25
- Technical
- Relative Strength Index (RSI)
- IFRX 45.40
- WYY 69.05
- Support Level
- IFRX $1.45
- WYY $5.26
- Resistance Level
- IFRX $1.77
- WYY $5.40
- Average True Range (ATR)
- IFRX 0.21
- WYY 0.30
- MACD
- IFRX -0.04
- WYY 0.02
- Stochastic Oscillator
- IFRX 24.94
- WYY 73.57
About IFRX InflaRx N.V.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.
About WYY WidePoint Corporation
WidePoint Corp is a provider of Technology Management as a Service (TMaaS) that consists of federally certified communications management, identity management, interactive bill presentment and analytics, and an Information Technology as a Service solution. Its solutions include Telecom Lifecycle Management, Digital billing communications solutions, and Mobile and Identity management. Geographically, the company generates a majority of its revenue from the United States and the rest from Europe.